BRAMITOB 300mg/4ml Price

Overview

Welcome to Dwaey, specifically on BRAMITOB 300mg/4ml Nebulization/Solution for page.
This medicine contains an important and useful components, as it consists of Tobramycin 300mg/4ml.
BRAMITOB 300mg/4ml is available in the market in concentration 300mg/4ml and in the form of Nebulization/Solution for.

CHIESI FARMACEUTICI S.p.A. is the producer of BRAMITOB 300mg/4ml and it is imported from ITALY, The most popular alternatives of BRAMITOB 300mg/4ml are listed downward .

Mode Of Action

Tobramycin acts by binding to 30S ribosomal subunits thus interfering with bacterial protein synthesis. It is active against many aerobic gram-negative bacteria and some aerobic gram-positive bacteria but inactive against Chlamydia, fungi, viruses, and most anaerobic bacteria.

Indication

• Ocular infection
• bacterial eye infection

Precaution

May result in overgrowth of nonsusceptible organisms, including fungi. Patient Counselling This drug may cause temporary blurred vision, if affected, do not drive or operate machinery. Contact lens wear is not recommended during treatment Lactation: Unknown whether drug is safe for nursing infants; discontinue, or do not nurse

Side Effects

• Localized ocular toxicity and hypersensitivity
• including increased lacrimation
• itching and edema of eyelid
• and conjunctival erythema (<3%) Sensitivity reaction
• punctate keratitis

Contra indication

This eye drop is contraindicated in epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella and other viral disease of the cornea and conjunctiva.It is contraindicated in mycobacterial infections of the eye caused by acid-fast bacilli such as Mycobacterium tuberculosis, Mycobacterium leprae, or Mycobacterium avium. Fungal diseases of eye, untreated purulent infection of the eye. Hypersensitivity to any component of the medication.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.